[1]
|
高翔, 梅长林. 《慢性肾脏病早期筛查、诊断及防治指南(2022年版)》解读[J]. 中国实用内科杂志, 2022, 42(9): 735-739.
|
[2]
|
Zhuang, Z., Tong, M., Clarke, R., et al. (2022) Probability of Chronic Kidney Disease and Associated Risk Factors in Chinese Adults: A Cross-Sectional Study of 9 Million Chinese Adults in the Meinian Onehealth Screen-ing Survey. Clinical Kidney Journal, 15, 2228-2236. https://doi.org/10.1093/ckj/sfac176
|
[3]
|
Matsushita, K., van der Velde, M., Astor, B.C., et al. (2010) Association of Estimated Glomerular Filtration Rate and Albuminuria with All-Cause and Cardiovascular Mortality in General Population Cohorts: A Collaborative Meta-Analysis. The Lancet, 375, 2073-2081. https://doi.org/10.1016/S0140-6736(10)60674-5
|
[4]
|
GBD 2019 Stroke Collaborators (2021) Global, Regional, and National Burden of Stroke and Its Risk Factors, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. The Lancet Neurology, 20, 795-820.
|
[5]
|
上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查、诊断及防治指南(2022年版) [J]. 中华肾脏病杂志, 2022, 38(5): 453-464.
|
[6]
|
Ene-Iordache, B., Perico, N., Bikbov, B., et al. (2016) Chronic Kidney Disease and Cardiovascular Risk in Six Regions of the World (ISN-KDDC): A Cross-Sectional Study. The Lancet Global Health, 4, e307-e319.
https://doi.org/10.1016/S2214-109X(16)00071-1
|
[7]
|
Zhang, L., Wang, F., Wang, L., et al. (2012) Prevalence of Chronic Kidney Disease in China: A Cross-Sectional Survey. The Lancet, 379, 815-822. https://doi.org/10.1016/S0140-6736(12)60033-6
|
[8]
|
Saran, R., Robinson, B., Abbott, K.C., et al. (2020) US Re-nal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 75, A6-A7.
https://doi.org/10.1053/j.ajkd.2019.09.003
|
[9]
|
Kelly, D.M., Ademi, Z., Doehner, W., et al. (2021) Chronic Kidney Disease and Cerebrovascular Disease: Consensus and Guidance from a KDIGO Controversies Conference. Stroke, 52, e328-e346.
https://doi.org/10.1161/STROKEAHA.120.029680
|
[10]
|
Shroff, G.R., Stoecker, R. and Hart, A. (2018) Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients with CKD: Pragmatic Considerations for the Clinician. American Journal of Kidney Diseases, 72, 717-727. https://doi.org/10.1053/j.ajkd.2018.02.360
|
[11]
|
Schwartzenberg, S., Lev, E.I., Sagie, A., et al. (2016) The Quan-dary of Oral Anticoagulation in Patients with Atrial Fibrillation and Chronic Kidney Disease. American Journal of Car-diology, 117, 477-482.
https://doi.org/10.1016/j.amjcard.2015.10.065
|
[12]
|
Andrassy, K.M. (2013) Comments on “KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease”. Kidney International, 84, 622-623. https://doi.org/10.1038/ki.2013.243
|
[13]
|
史永红, 张春东, 吴广礼. 抗凝相关性肾病发病及高危因素研究进展[J]. 临床误诊误治, 2021, 34(10): 113-116.
|
[14]
|
Reilly, E.B., Perry, A., Fujita, K., et al. (1964) Haematuria and Anti-coagulants. The Lancet, 1, 554.
https://doi.org/10.1016/S0140-6736(64)92940-X
|
[15]
|
Li, J., Padala, S.A., Hinnant, G., et al. (2019) My Bleeding Nephrons! Journal of Investigative Medicine High Impact Case Reports, 7. https://doi.org/10.1177/2324709619858126
|
[16]
|
Chen, S., Liao, D., Yang, M., et al. (2023) Anticoagulant-Related Nephropathy Induced by Direct-Acting Oral Anticoagulants: Clinical Characteristics, Treatments and Outcomes. Throm-bosis Research, 222, 20-23.
https://doi.org/10.1016/j.thromres.2022.12.002
|
[17]
|
Trujillo, H., Sandino, J., Cavero, T., et al. (2022) IgA Nephropathy Is the Most Common Underlying Disease in Patients with Anticoagulant-Related Nephropathy. Kidney In-ternational Reports, 7, 831-840.
https://doi.org/10.1016/j.ekir.2022.01.1048
|
[18]
|
Belcic, M.T., Kojc, N., Frelih, M., et al. (2021) Management of Anticoagulant-Related Nephropathy: A Single Center Experience. Journal of Clinical Medicine, 10, Article No. 796. https://doi.org/10.3390/jcm10040796
|
[19]
|
Zeni, L., Manenti, C., Fisogni, S., et al. (2020) Acute Kidney Injury Due to Anticoagulant-Related Nephropathy: A Suggestion for Therapy. Case Reports in Nephrology, 2020, Article ID: 8952670.
https://doi.org/10.1155/2020/8952670
|
[20]
|
Wheeler, D.S., Giugliano, R.P. and Rangaswami, J. (2016) Anticoagu-lation-Related Nephropathy. Journal of Thrombosis and Haemostasis, 14, 461-467. https://doi.org/10.1111/jth.13229
|
[21]
|
Brodsky, S.V., Nadasdy, T., Rovin, B.H., et al. (2011) Warfarin-Related Nephropathy Occurs in Patients with and without Chronic Kidney Disease and Is Associated with an Increased Mortality Rate. Kidney International, 80, 181-189. https://doi.org/10.1038/ki.2011.44
|
[22]
|
Quinn, L.M., Richardson, R., Cameron, K.J., et al. (2015) Evaluating Time in Therapeutic Range for Hemodialysis Patients Taking Warfarin. Clinical Nephrology, 83, 80-85. https://doi.org/10.5414/CN108400
|
[23]
|
Bonde, A.N., Lip, G.Y., Kamper, A.L., et al. (2016) Renal Function and the Risk of Stroke and Bleeding in Patients with Atrial Fibrillation: An Observational Cohort Study. Stroke, 47, 2707-2713.
https://doi.org/10.1161/STROKEAHA.116.014422
|
[24]
|
Chang, S.H., Wu, C.V., Yeh, Y.H., et al. (2019) Efficacy and Safety of Oral Anticoagulants in Patients with Atrial Fibrillation and Stages 4 or 5 Chronic Kidney Disease. The American Journal of Medicine, 132, 1335-1343.
https://doi.org/10.1016/j.amjmed.2019.06.006
|
[25]
|
Altawalbeh, S.M., Alshogran, O.Y. and Smith, K.J. (2018) Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease. Value in Health, 21, 1365-1372.
https://doi.org/10.1016/j.jval.2018.06.009
|
[26]
|
Ning, X., Kuang, Y., Yang, G., et al. (2021) Influence of Renal In-sufficiency on Anticoagulant Effects and Safety of Warfarin in Chinese Patients: Analysis from a Randomized Controlled Trial. Naunyn-Schmiedeberg’s Archives of Pharmacology, 394, 1275-1283. https://doi.org/10.1007/s00210-020-02037-3
|
[27]
|
Reinecke, H., Nabauer, M., Gerth, A., et al. (2015) Morbidity and Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease. Kidney International, 87, 200-209. https://doi.org/10.1038/ki.2014.195
|
[28]
|
Goto, S., Angchaisuksiri, P., Bassand, J.P., et al. (2019) Management and 1-Year Outcomes of Patients with Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results from the Prospective GARFIELD-AF Registry. Journal of the American Heart Association, 8, e10510.
|
[29]
|
Kruger, T. and Floege, J. (2014) Vitamin K Antagonists: Beyond Bleeding. Seminars in Dialysis, 27, 37-41.
https://doi.org/10.1111/sdi.12175
|
[30]
|
January, C.T., Wann, L.S., Calkins, H., et al. (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Re-port of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 74, 104-132. https://doi.org/10.1016/j.jacc.2019.01.011
|
[31]
|
Obrezan, A.G. and Zemchenkov, A.Y. (2018) Chronic Kidney Disease as Basis of High Thrombotic and Bleeding Risk in Patients with Atrial Fibrillation: Place of Oral Anticoagulants. Kardiologiia, 58, 60-70.
https://doi.org/10.18087/cardio.2018.4.10111
|
[32]
|
Diener, H.C., Aisenberg, J., Ansell, J., et al. (2017) Choosing a Particular Oral Anticoagulant and Dose for Stroke Prevention in Individual Patients with Non-Valvular Atrial Fibrillation: Part 2. European Heart Journal, 38, 860-868.
https://doi.org/10.1093/eurheartj/ehw069
|
[33]
|
Mlodawska, E., Lopatowska, P., Malyszko, J., et al. (2018) Atrial Fibrillation in Dialysis Patients: Is There a Place for Non-Vitamin K Antagonist Oral Anticoagulants? International Urology and Nephrology, 50, 1633-1642.
https://doi.org/10.1007/s11255-018-1877-y
|
[34]
|
Steffel, J., Collins, R., Antz, M., et al. (2021) 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 23, 1612-1676.
https://doi.org/10.1093/europace/euab065
|
[35]
|
Ha, J.T., Neuen, B.L., Cheng, L.P., et al. (2019) Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Annals of Internal Medicine, 171, 181-189.
https://doi.org/10.7326/M19-0087
|
[36]
|
Rossini, R., Casula, M. and Ferlini, M. (2021) Atrial Fibrillation in Ad-vanced Renal Failure: Are There Alternative Solutions to Warfarin-Dicumarol? European Heart Journal Supplements, 23, E138-E141.
https://doi.org/10.1093/eurheartj/suab109
|
[37]
|
Maegdefessel, L., Spin, J.M., Azuma, J., et al. (2010) New Options with Dabigatran Etexilate in Anticoagulant Therapy. Vascular Health and Risk Management, 6, 339-349. https://doi.org/10.2147/VHRM.S8942
|
[38]
|
Pollack, C.J., Reilly, P.A., van Ryn, J., et al. (2017) Idarucizumab for Dabigatran Reversal—Full Cohort Analysis. The New England Journal of Medicine, 377, 431-441. https://doi.org/10.1056/NEJMoa1707278
|
[39]
|
Ravera, M., Bussalino, E., Fusaro, M., et al. (2020) Systematic DOACs Oral Anticoagulation in Patients with Atrial Fibrillation and Chronic Kidney Disease: The Nephrologist’s Per-spective. Journal of Nephrology, 33, 483-495.
https://doi.org/10.1007/s40620-020-00720-5
|
[40]
|
See, L.C., Lee, H.F., Chao, T.F., et al. (2021) Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Popula-tion-Based Cohort Study and Meta-Analysis. Cardiovascular Drugs and Therapy, 35, 975-986. https://doi.org/10.1007/s10557-020-07108-4
|